BR112023006154A2 - Cápsulas softgel de liberação modificada - Google Patents

Cápsulas softgel de liberação modificada

Info

Publication number
BR112023006154A2
BR112023006154A2 BR112023006154A BR112023006154A BR112023006154A2 BR 112023006154 A2 BR112023006154 A2 BR 112023006154A2 BR 112023006154 A BR112023006154 A BR 112023006154A BR 112023006154 A BR112023006154 A BR 112023006154A BR 112023006154 A2 BR112023006154 A2 BR 112023006154A2
Authority
BR
Brazil
Prior art keywords
release
dependent
softgel capsules
capsules
modified release
Prior art date
Application number
BR112023006154A
Other languages
English (en)
Inventor
Sukuru Karunakar
Fang Qi
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of BR112023006154A2 publication Critical patent/BR112023006154A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CÁPSULAS SOFTGEL DE LIBERAÇÃO MODIFICADA. A presente invenção refere-se a cápsulas softgel de liberação modificada, incluindo uma composição de envoltório dependente do pH, que encapsula uma composição de preenchimento de liberação controlada, métodos de preparação das mesmas e métodos de uso das mesmas. A composição de envoltório dependente do pH pode ser caracterizada pelo fato de que a natureza de liberação retardada das cápsulas pode ser obtida sem um revestimento dependente do pH separado ou polímeros dependentes do pH convencionais adicionados. Os softgéis oferecem uma plataforma de liberação controlada dupla que facilita a distribuição do agente ativo para um local-alvo no trato gastrointestinal e um perfil de liberação controlada do agente ativo no referido local-alvo no trato gastrointestinal.
BR112023006154A 2020-10-16 2021-10-15 Cápsulas softgel de liberação modificada BR112023006154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063092762P 2020-10-16 2020-10-16
PCT/US2021/071900 WO2022082222A1 (en) 2020-10-16 2021-10-15 Modified release softgel capsules

Publications (1)

Publication Number Publication Date
BR112023006154A2 true BR112023006154A2 (pt) 2023-05-09

Family

ID=81208677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006154A BR112023006154A2 (pt) 2020-10-16 2021-10-15 Cápsulas softgel de liberação modificada

Country Status (14)

Country Link
US (1) US20230390210A1 (pt)
EP (1) EP4228597A1 (pt)
JP (1) JP2023547062A (pt)
KR (1) KR20230088388A (pt)
CN (1) CN116322655A (pt)
AR (1) AR123805A1 (pt)
AU (1) AU2021362248A1 (pt)
BR (1) BR112023006154A2 (pt)
CA (1) CA3194160A1 (pt)
CO (1) CO2023005753A2 (pt)
IL (1) IL301715A (pt)
MX (1) MX2023004418A (pt)
TW (1) TW202228656A (pt)
WO (1) WO2022082222A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
GB201304662D0 (en) * 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2950311C (en) * 2014-06-23 2019-05-14 Banner Life Sciences Llc All natural enteric soft capsules comprising active ingredients
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
BR112021005923A2 (pt) * 2018-10-16 2021-06-29 Bayer Healthcare Llc cápsulas de gelatina mole com matriz de enchimento polimérica sólida ou semelhante a gel
CN114845569A (zh) * 2019-10-28 2022-08-02 R.P.谢勒技术有限公司 较高ph环境中的延迟释放软凝胶胶囊

Also Published As

Publication number Publication date
TW202228656A (zh) 2022-08-01
AU2021362248A9 (en) 2024-05-02
MX2023004418A (es) 2023-05-04
US20230390210A1 (en) 2023-12-07
AU2021362248A1 (en) 2023-06-01
AR123805A1 (es) 2023-01-11
KR20230088388A (ko) 2023-06-19
CO2023005753A2 (es) 2023-05-29
IL301715A (en) 2023-05-01
CN116322655A (zh) 2023-06-23
CA3194160A1 (en) 2022-04-21
WO2022082222A1 (en) 2022-04-21
JP2023547062A (ja) 2023-11-09
EP4228597A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
KR102337809B1 (ko) 리나클로타이드의 지연 방출 조성물
JP6030643B2 (ja) ガン細胞の増殖を阻害するアミド誘導体および非金属塩滑沢剤を含む医薬組成物
BR112021024375A2 (pt) Cápsulas de softgel de liberação retardada
BR112018008805A8 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
Li et al. Synergistic antidepressant-like effect of ferulic acid in combination with piperine: involvement of monoaminergic system
BR112012026223A2 (pt) formulação adequada para o uso em ração animal, uso, e ração para animais.
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
BR112013028453B8 (pt) Uso de uma composição de revestimento, formas de dosagem farmacêuticas ou nutracêuticas gastrorresistentes, e composição do polímero do núcleo/invólucro
BR112022000413A2 (pt) Formulação de longa duração contendo rivastigmina e método para preparar a mesma
BR112022024391A2 (pt) Cápsulas de gelatina mole para liberação retardada
MX2023005451A (es) Capsulas de gel blando de liberacion retardada.
BR112022012118A2 (pt) Kit para preparar uma composição de nanopartículas
BR112023006154A2 (pt) Cápsulas softgel de liberação modificada
BR112015021630A2 (pt) estabilização de fármacos sensíveis à umidade
EA201690768A1 (ru) Состав, предотвращающий некротический энтерит у домашних птиц
BR112021026848A2 (pt) Composição de resina epóxi estável ao armazenamento
BR112019008402A2 (pt) cápsula compósita e método para preparar a cápsula compósita
TR201616998A1 (en) DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
RU2018100755A (ru) Комбинированный препарат мозаприда и рабепразола
BR112023002161A2 (pt) Formas sólidas de dosagem de palbociclibe
EA201700370A1 (ru) Фармацевтическая композиция с модифицированным отсроченным и длительным высвобождением, содержащая аспарагинаты
PE20171340A1 (es) Composicion farmaceutica para el tratamiento de enfermedades gastrointestinales
JP2015193635A (ja) 速溶性防湿フィルムコーティング製剤及びその製造方法
BR112021006627A2 (pt) composição líquida encapsulada
BR112021017876A2 (pt) Estabilidade de api aperfeiçoada em cápsulas gelatinosas